Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study.
Meca-Lallana JE, Gómez-Ballesteros R, Pérez-Miralles F, Forero L, Sepúlveda M, Calles C, Martínez-Ginés ML, González-Suárez I, Boyero S, Romero-Pinel L, Sempere ÁP, Meca-Lallana V, Querol L, Costa-Frossard L, Prefasi D, Maurino J. Meca-Lallana JE, et al. Neurol Ther. 2022 Sep;11(3):1101-1116. doi: 10.1007/s40120-022-00356-6. Epub 2022 May 6. Neurol Ther. 2022. PMID: 35524037 Free PMC article.
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.
Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, Alvarez de Arcaya A, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramió-Torrentà L, Cobo-Calvo A, Viñals M, de Andrés C, Meca-Lallana V, Cervelló A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A. Sepúlveda M, et al. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225. doi: 10.1212/NXI.0000000000000225. eCollection 2016 Jun. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27144216 Free PMC article.
[Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Mallada-Frechin J, Meca-Lallana V, Barrero F, Martinez-Gines ML, Marzo-Sola ME, Ricart J, Garcia E, En Representacion de Los Investigadores Del Estudio Ms Next ERLIDEMN. Mallada-Frechin J, et al. Rev Neurol. 2018 Sep 1;67(5):157-167. Rev Neurol. 2018. PMID: 30047118 Free article. Spanish.
Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders.
Carreón Guarnizo E, Hernández Clares R, Castillo Triviño T, Meca Lallana V, Arocas Casañ V, Iniesta Martínez F, Olascoaga Urtaza J, Meca Lallana JE. Carreón Guarnizo E, et al. Neurologia (Engl Ed). 2022 Apr;37(3):178-183. doi: 10.1016/j.nrl.2018.12.013. Epub 2019 Mar 28. Neurologia (Engl Ed). 2022. PMID: 30928236 Free article. English, Spanish.
Perception of stigma in patients with primary progressive multiple sclerosis.
Pérez-Miralles F, Prefasi D, García-Merino A, Ara JR, Izquierdo G, Meca-Lallana V, Gascón F, Martínez-Ginés ML, Ramió-Torrentà L, Costa-Frossard L, Fernández Ó, Moreno-García S, Maurino J, Casanova-Estruch B. Pérez-Miralles F, et al. Mult Scler J Exp Transl Clin. 2019 May 22;5(2):2055217319852717. doi: 10.1177/2055217319852717. eCollection 2019 Apr-Jun. Mult Scler J Exp Transl Clin. 2019. PMID: 31205741 Free PMC article.
Assessing fatigue in multiple sclerosis: Psychometric properties of the five-item Modified Fatigue Impact Scale (MFIS-5).
Meca-Lallana V, Brañas-Pampillón M, Higueras Y, Candeliere-Merlicco A, Aladro-Benito Y, Rodríguez-De la Fuente O, Salas-Alonso E, Maurino J, Ballesteros J. Meca-Lallana V, et al. Mult Scler J Exp Transl Clin. 2019 Nov 9;5(4):2055217319887987. doi: 10.1177/2055217319887987. eCollection 2019 Oct-Dec. Mult Scler J Exp Transl Clin. 2019. PMID: 31741743 Free PMC article.
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
Meca-Lallana J, Ayuso T, Martínez-Yelamos S, Durán C, Contreras Martín Y, Herrera Navarro N, Pérez Sempere A, Álvarez-Cermeño JC, Millán Pascual J, Meca-Lallana V, Romero Sevilla R, Ricart J. Meca-Lallana J, et al. Eur Neurol. 2020;83(1):25-33. doi: 10.1159/000505778. Epub 2020 Mar 18. Eur Neurol. 2020. PMID: 32187609 Free PMC article.
Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
Barrero F, Mallada-Frechin J, Martínez-Ginés ML, Marzo ME, Meca-Lallana V, Izquierdo G, Ara JR, Oreja-Guevara C, Meca-Lallana J, Forero L, Sánchez-Vera I, Moreno MJ; in representation of the MS NEXT study investigators. Barrero F, et al. PLoS One. 2020 Apr 2;15(4):e0230846. doi: 10.1371/journal.pone.0230846. eCollection 2020. PLoS One. 2020. PMID: 32240213 Free PMC article.
[EMCAM (Multiple Sclerosis Autonomous Community of Madrid) document for the management of patients with multiple sclerosis during the SARS-CoV-2 pandemic].
Costa-Frossard L, Moreno-Torres I, Meca-Lallana V, García-Domínguez JM, En Representación Del Grupo de Estudio de Enfermedades Desmielinizantes de la Comunidad Autónoma de Madrid ERDGEEDCAM. Costa-Frossard L, et al. Rev Neurol. 2020 May 1;70(9):329-340. doi: 10.33588/rn.7009.2020155. Rev Neurol. 2020. PMID: 32329046 Free article. Review. Spanish.
60 results